The article reports that pharmaceutical company Merck is in talks to buy biotech firm Revolution Medicines, which develops cancer drugs. According to sources cited in the Financial Times, a price range of around $28 billion to $32 billion is being discussed. The agreement has not yet been finalized and it is expected that the eventual completion of the transaction will take at least a few more weeks. Other big pharmaceutical companies are also reported to be interested in Revolution Medicines, so it is not certain that Merck will be the buyer. Shares of Revolution Medicines rose sharply, up about 15% in over-the-counter trading, following the news of the talks. Revolution Medicines is described as a company focused on targeted therapies in oncology.